In line with a Biden administration proposal, pharmaceutical giant Eli Lilly is cutting the price of its most commonly prescribed insulins by 70 percent and capping out-of-pocket costs at $35 or less per month.  

"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change," said CEO David A. Ricks. "The aggressive price cuts we're announcing today should make a real difference for Americans with diabetes. Because these price cuts will take time for the insurance and pharmacy system to implement, we are taking the additional step to immediately cap out-of-pocket costs for patients who use Lilly insulin and are not covered by the recent Medicare Part D cap."

Here is a list of the drugs seeing price cuts, via Eli Lilly: 

"We are driving for change in repricing older insulins, but we know that 7 out of 10 Americans don't use Lilly insulin," said Ricks. We are calling on policymakers, employers and others to join us in making insulin more affordable."

The company said it will launch a nationwide awareness campaign in the coming weeks to spread the word about its new lower costs. 

Activists have long called for more affordable insulin, which even with insurance can place a financial burden on those in need. The American Diabetes Association has found that there are approximately $15 billion in excess costs for insulin in 2017. 

Share:
More In Business
Eyeing Some Cool Collectibles at New York Comic Con
If you have some older comic books stashed away in your attic, basement or closet, make sure to check their condition as they could be traded for serious cash. Cheddar News' Michelle Castillo at New Yor Comic Con spoke with Chris D'Lando, event manager with NYCC for Reedpop; Andy Mourat, co-founder and president of MetaZoo; and Julian Montoya, senior vice president of The Noble Collection, to get their thoughts.
How Traders Are Bracing for Upcoming Fed Meeting & Amid Geopolitical Conflicts
Eliott Wellenbach, vice president and institutional ETF strategist with Direxion, joined Cheddar News to explain how investors are bracing for interest rate hikes after last week's inflation report and ahead of the Fed's upcoming meeting. Wellenbach also discussed how traders are taking advantage of volatility as earnings season continues and amid geopolitical conflicts.
Ready 4 Work Offers Tips for Writing Resumes
One of the most difficult parts of a job search is writing resumes. Cheddar News' docuseries Ready 4 Work explores the pitfalls of that and helps job seekers stand out from all those other applicants.
Load More